Antibodies to human vascular endothelial growth factor 2 and...

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387100, C530S387300, C530S388100, C530S388150, C530S389100, C530S391300, C435S007100, C424S130100, C424S133100, C424S139100

Reexamination Certificate

active

07576189

ABSTRACT:
Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Also disclosed is a method of using such polypeptide for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antagonists to inhibit tumor growth, inflammation and to treat diabetic retinopathy, rheumatoid arthritis and psoriasis. Diagnostic methods for detecting mutations in the VEGF2 coding sequence and alterations in the concentration of VEGF2 protein in a sample derived from a host are also disclosed.

REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5283354 (1994-02-01), Lemischka
patent: 5326695 (1994-07-01), Andersson et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5633147 (1997-05-01), Meissner et al.
patent: 5652225 (1997-07-01), Isner
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5861301 (1999-01-01), Terman et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6121246 (2000-09-01), Isner
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6608182 (2003-08-01), Rosen et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 6734285 (2004-05-01), Hu et al.
patent: 6824777 (2004-11-01), Alitalo et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7109308 (2006-09-01), Rosen et al.
patent: 7115392 (2006-10-01), Rosen et al.
patent: 7153827 (2006-12-01), Hu et al.
patent: 7153942 (2006-12-01), Hu et al.
patent: 7186688 (2007-03-01), Hu et al.
patent: 7208582 (2007-04-01), Rosen et al.
patent: 7223724 (2007-05-01), Alderson et al.
patent: 7227005 (2007-06-01), Hu et al.
patent: 7273751 (2007-09-01), Coleman
patent: 7402312 (2008-07-01), Rosen et al.
patent: 7439333 (2008-10-01), Hu et al.
patent: 2003/0215921 (2003-11-01), Coleman
patent: 2004/0214286 (2004-10-01), Hu et al.
patent: 2005/0059117 (2005-03-01), Rosen et al.
patent: 2005/0176103 (2005-08-01), Hu et al.
patent: 2005/0181979 (2005-08-01), Alderson et al.
patent: 2005/0192429 (2005-09-01), Rosen et al.
patent: 2005/0232921 (2005-10-01), Rosen et al.
patent: 2006/0014252 (2006-01-01), Lyman
patent: 2006/0025331 (2006-02-01), Hu et al.
patent: 2006/0057117 (2006-03-01), Coleman
patent: 710696 (1999-09-01), None
patent: 0186084 (1986-07-01), None
patent: 0399816 (1990-11-01), None
patent: 0476983 (1992-03-01), None
patent: 0506477 (1992-09-01), None
patent: 64-38100 (1989-02-01), None
patent: 2-117698 (1990-05-01), None
patent: WO 91/02058 (1991-02-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO 95/19985 (1995-07-01), None
patent: WO 95/24414 (1995-09-01), None
patent: WO 95/24473 (1995-12-01), None
patent: WO 96/05856 (1996-02-01), None
patent: WO 96/39515 (1996-12-01), None
patent: WO 97/00271 (1997-01-01), None
patent: WO 97/05250 (1997-02-01), None
patent: WO 97/08320 (1997-03-01), None
patent: WO 97/09427 (1997-03-01), None
patent: WO 97/17442 (1997-05-01), None
patent: WO 97/19694 (1997-06-01), None
patent: WO 98/06844 (1998-02-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/24811 (1998-06-01), None
patent: WO 98/33917 (1998-06-01), None
patent: WO 98/39035 (1998-09-01), None
patent: WO 98/49300 (1998-11-01), None
patent: WO 98/55619 (1998-12-01), None
patent: WO 98/56936 (1998-12-01), None
patent: WO 99/02545 (1999-01-01), None
patent: WO 99/08522 (1999-02-01), None
patent: WO 99/20749 (1999-04-01), None
patent: WO 99/21590 (1999-05-01), None
patent: WO 99/46364 (1999-09-01), None
patent: WO 00/45835 (2000-08-01), None
patent: WO 00/73430 (2000-12-01), None
patent: WO 00/75163 (2000-12-01), None
patent: WO 01/57226 (2001-08-01), None
patent: WO 01/58956 (2001-08-01), None
patent: WO 02/11769 (2002-02-01), None
patent: WO 02/083704 (2002-10-01), None
patent: WO 02/083849 (2002-10-01), None
patent: WO 02/083850 (2002-10-01), None
patent: WO 03/097660 (2003-11-01), None
patent: 9-403464 (1996-01-01), None
U.S. Appl. No. 09/257,272, inventors Hu et al., filed Feb. 25, 1999 (Not Published).
U.S. Appl. No. 09/499,468, inventors Alderson et al., filed Feb. 7, 2000 (Not Published).
U.S. Appl. No. 11/730,696, inventors Rosen et al., filed Apr. 3, 2007 (Not Published).
Dermer, G.B., “Another Anniversary for the War on Cancer,”Bio/Technol.12:320, Wiley-VCH Verlag GmbH & Co. (Mar. 1994).
Duda, D.G., et al., “VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects,”Trends Molec. Med. 13(6):223-230, Elsevier Ltd. (Apr. 2007).
Gura, T., “Systems for Identifying New Drugs Are Ofter Faulty,”Science 278(5340):1041-1042, American Association for the Advancement of Science (Nov. 1997).
Landolfi, N.F., et al., “The Integrity of the Ball-and-Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody,”J. Immunol. 166:1748-1754, The American Association of Immunologists (Feb. 2001).
Liu, Z., et al., “Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II ffromDrosophila melanogaster,” J. Mol. Recognit. 12:103-111, John Wiley & Sons, Ltd. (Mar. 1999).
Achen et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4),”Proc. Natl. Acad. Sci.(USA) 95:548-553, National Academy of Sciences (Jan. 1998).
Alderson et al., “Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro,”Keystone Symposia, Ocular Cell and Molec. Bio.202 (1999).
Altshuler et al., “Taurine promotes the differentiation of a vertebrate retinal cell type in vitro,”Development I 19:1317-1328, Company of Biologists Limited (Dec. 1993).
Andersson et al., “Assignment of interchain disulfide bonds in platelet-derived growth factor (PDFG) as evidence for agonist activity of monomeric PDGF,”J. Bio. Chem. 267:11260-11266, American Society for Biochemistry and Molecular Biology (1992).
Andersson, W.F. “Human gene therapy,”Science 256:808-813, American Association for the Advancement of Science (1992).
Aprelikova et al., “FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter,”Cancer Res. 52:746-748, American Association for Cancer Research (1992).
Bell et al., “Human epidermanl growth factor precursor: cDNA sequence, expression in vitro and gene organization,”Nucl. Acids Res. 14:8427-8446, Oxford University Press (1986).
Bellomo et al., “Mice Lacking the Vascular Endothelial Growth Factor-B Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ishemia,”Circ. Research 86:e29-e35, Lippincott, Williams & Wilkins (Feb. 2000).
Berse et al., “Vascular permeability factor (vacular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors,”Mol. Biol. Cell. 3:211-220, American Society for Cell Biology (1992).
Betsholtz et al., “cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines,”Nature 320:695-699, Macmillan Publishers (1986).
Bocker-Meffert et al., “Erythropoietin and VEGF Promote Neural Outgrowth f

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies to human vascular endothelial growth factor 2 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to human vascular endothelial growth factor 2 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to human vascular endothelial growth factor 2 and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4128590

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.